# A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)

Study · id `cardio:ct-nct05952869` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05952869](<https://clinicaltrials.gov/study/NCT05952869>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05952869

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 303 participants.

## Technical summary

Registry record NCT05952869. Randomized; triple masking; primary purpose treatment. Start 2023-08-08 (actual); primary completion 2025-04-07 (actual). Results posted on 2026-02-24.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 303 participants (enrolled count; ClinicalTrials.gov record NCT05952869, source copy `cardio:ctgov-nct05952869-2026-02-24`, retrieved 2026-10-31)
- Started: 2023-08-08 (actual) (ClinicalTrials.gov record NCT05952869, source copy `cardio:ctgov-nct05952869-2026-02-24`, retrieved 2026-10-31)
- Primary completion: 2025-04-07 (actual) (ClinicalTrials.gov record NCT05952869, source copy `cardio:ctgov-nct05952869-2026-02-24`, retrieved 2026-10-31)
- Completion: 2025-04-07 (actual) (ClinicalTrials.gov record NCT05952869, source copy `cardio:ctgov-nct05952869-2026-02-24`, retrieved 2026-10-31)
- Results first posted: 2026-02-24 (ClinicalTrials.gov record NCT05952869, source copy `cardio:ctgov-nct05952869-2026-02-24`, retrieved 2026-10-31)
- Countries: United States; Australia; Brazil; Canada; Chile; Colombia; Czechia; Finland; Hong Kong SAR China; Hungary; Israel; Netherlands; New Zealand; Norway; Singapore; Spain; Taiwan (ClinicalTrials.gov record NCT05952869, source copy `cardio:ctgov-nct05952869-2026-02-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05952869-2026-02-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
- Condition: Hypercholesterolemia
- Condition: Familial Hypercholesterolemia
- Intervention (Drug): Enlicitide Decanoate
- Intervention (Drug): Placebo
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Familial hypercholesterolemia (`cardio:familial-hypercholesterolemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial (`cardio:pubmed-41206969`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e6275873d5a5c8f806b671b1d81e826b5f25dd39d8ab35b44864e2e617f6970c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
